US20020128302A1 - Use of central cannabinoid receptor antagonists for the preparation of drugs - Google Patents
Use of central cannabinoid receptor antagonists for the preparation of drugs Download PDFInfo
- Publication number
- US20020128302A1 US20020128302A1 US10/044,531 US4453102A US2002128302A1 US 20020128302 A1 US20020128302 A1 US 20020128302A1 US 4453102 A US4453102 A US 4453102A US 2002128302 A1 US2002128302 A1 US 2002128302A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- group
- hydrogen
- substituted
- defined above
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *C.*OC.OC(CNC1CCC2=C(C=CC=C2)C1)C1=CC=CC=C1 Chemical compound *C.*OC.OC(CNC1CCC2=C(C=CC=C2)C1)C1=CC=CC=C1 0.000 description 9
- JZCPYUJPEARBJL-UHFFFAOYSA-N CC1=C(C2=CC=C(Cl)C=C2)N(C2=CC=C(Cl)C=C2Cl)N=C1C(=O)NN1CCCCC1 Chemical compound CC1=C(C2=CC=C(Cl)C=C2)N(C2=CC=C(Cl)C=C2Cl)N=C1C(=O)NN1CCCCC1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a novel use of antagonists of the central cannabinoid receptors or so-called CB 1 receptors.
- the invention relates to the use of CB 1 receptor antagonists for the preparation of drugs useful in the treatment of appetency disorders.
- the purpose of drugs useful in the treatment of appetency disorders is to regulate consumption desires, particularly desires to consume sugars, carbohydrates, alcohol or drugs and more generally to consume appetizing ingredients.
- disorders of food behaviors especially those liable to cause excess weight, irrespective of its origin, for example: bulimia, appetency for sugars, non-insulin-dependent diabetes.
- Substances are understood as meaning appetizing ingredients such as sugars, carbohydrates, alcohols or drugs.
- the present invention therefore further relates to the use of a CB 1 receptor antagonist for the preparation of drugs useful in the treatment of bulimia and obesity, including obesity associated with type II diabetes (non-insulin-dependent diabetes), or more generally any disease resulting in the patient becoming overweight, and in the treatment of drug abuse or drug dependency.
- a CB 1 receptor antagonist for the preparation of drugs useful in the treatment of bulimia and obesity, including obesity associated with type II diabetes (non-insulin-dependent diabetes), or more generally any disease resulting in the patient becoming overweight, and in the treatment of drug abuse or drug dependency.
- Delta-9-tetrahydrocannabinol is the main active constituent extracted from Cannabis sativa (Tuner, 1985; in Marijuana, 84, Ed. Harvey, D Y, IRL Press, Oxford).
- N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide also called SR 141716, of the formula
- SR 141716 A is the hydrochloride of SR 141716.
- delta-9-tetrahydrocannabinol whose international non-proprietary name is Dronabinol, is used in the treatment of anorexia, especially in patients suffering from AIDS (J. Pain Symptom Manage., 1995, 10 (2), 89-97) or cancer (J. Palliat. Care, 1994, 10 (1), 14-18).
- SR 141716 and its salts which are central cannabinoid receptor antagonists, can be used in the treatment of appetite disorders, especially as anorexigenic agents, and in the treatment of disorders associated with the use of psychotropic substances.
- CB 1 receptor antagonists have a specific property by acting electively on consumption behavior disorders pertaining to appetizing substances.
- a CB 1 receptor antagonist makes it possible to regulate the desire to consume non-essential food items such as excess sugars, excess carbohydrates, alcohol or drugs.
- the present invention relates to the use of a CB 1 receptor antagonist for the preparation of drugs useful in the treatment of appetency disorders.
- CB 1 receptor antagonists appropriate for the purposes of the invention are particularly the compounds of the formula
- R 1 is hydrogen, a fluorine, a hydroxyl, a (C 1 -C 5 )alkoxy, a (C 1 -C 5 )alkylthio, a hydroxy(C 1 -C 5 )alkoxy, a group —NR 10 R 11 , a cyano, a (C 1 -C 5 )alkylsulfonyl or a (C 1 -C 5 )alkylsulfinyl;
- R 2 and R 3 are a (C 1 -C 4 )alkyl or, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated 5- to 10-membered heterocyclic radical which is unsubstituted or monosubstituted or polysubstituted by a (C 1 -C 3 )alkyl or by a (C 1 -C 3 )alkoxy;
- R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are each independently hydrogen, a halogen or a trifluoromethyl, and if R 1 is a fluorine, R 4 , R 5 , R 6 , R 7 , R 8 and/or R 9 can also be a fluoromethyl, with the proviso that at least one of the substituents R 4 or R 7 is other than hydrogen; and
- R 10 and R 11 are each independently hydrogen or a (C 1 -C 5 )alkyl, or R 10 , and R 11 , together with the nitrogen atom to which they are bonded, form a heterocyclic radical selected from pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl and piperazin-1-yl, which is unsubstituted or substituted by a (C 1 -C 4 )alkyl,
- the present invention relates to the use of N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide, its pharmaceutically acceptable salts and their solvates for the preparation of drugs useful in the treatment of appetency disorders.
- the CB 1 receptor antagonists can also be used in association with another active principle for the preparation of drugs useful in the treatment of appetency disorders, especially in the treatment of disorders of food behaviors; it is possible to use a pharmaceutical composition comprising a CB 1 receptor antagonist in association with a compound for regulating metabolic disorders, especially a ⁇ 3 -adrenergic receptor agonist, hereafter called a ⁇ 3 -agonist.
- the present invention further relates to pharmaceutical compositions containing a CB 1 receptor antagonist and a regulator of metabolic disorders, for example a hypolipemic, hypolydemic or lipolytic. More particularly, the present invention relates to pharmaceutical compositions containing a CB 1 receptor antagonist and a ⁇ 3 -agonist.
- ⁇ 3 -agonists which can be used according to the present invention are the compounds of the formula
- X is hydrogen, a halogen, a trifluoromethyl or a (C 1 -C 4 )alkyl
- R is hydrogen or a methyl which is unsubstituted or substituted by a carboxyl or an alkoxycarbonyl in which the alkoxy is (C 1 -C 6 ),
- N-[(2S)-7-Ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphth-2-yl]-(2R)-2-(3-chlorophenyl)-2-hydroxyethanamine (SR 58611) and its pharmaceutically acceptable salts are very particularly advantageous, especially its salt with hydrochloric acid, SR 58611 A.
- ⁇ 3 -agonists which can be used according to the present invention are the compounds of the formula
- n 1,2 or 3;
- A is a benzofuran-2-yl or a phenyl which is unsubstituted or substituted by one or two halogen atoms or by a (C 1 -C 4 )alkyl or a trifluoromethyl;
- R′ is:
- a functional group selected from the following groups: hydroxyl; (C 1 -C 6 )alkoxy; (C 2 -C 6 )alkenyloxy; (C 2 -C 6 )alkynyloxy; (C 3 -C 8 )cycloalkoxy; (C 3 -C 8 )cycloalkyl(C 1 -C 6 )alkoxy; benzyloxy; phenoxy; mercapto; (C 1 -C 6 )alkylthio; (C 2 -C 6 )alkenylthio; (C 2 -C 6 )alkynylthio; (C 3 -C 8 )cycloalkylthio; (C 3 -C 8 )cycloalkyl(C 1 -C 6 )alkylthio; benzylthio; phenylthio; (C 1 -C 6 )alkylsulfinyl; (C 2 -C 6 )
- a group R′′′ selected from the following groups: (C 1 -C 6 )alkyl substituted by a functional group; (C 2 -C 6 )alkenyl substituted by a functional group; (C 2 -C 6 )alkynyl substituted by a functional group; phenyl(C 1 -C 6 )alkyl substituted on the phenyl by a (C 1 -C 6 )alkyl or by a functional group; phenyl(C 2 -C 6 )alkenyl substituted on the phenyl by a (C 1 -C 6 )alkyl or by a functional group; phenyl(C 2 -C 6 )alkynyl substituted on the phenyl by a (C 1 -C 6 )alkyl or by a functional group; benzyl substituted on the phenyl by a (C 1 -C 6 )alkyl or by a functional group; and
- a group NR′′′R 0 in which R′′′ is as defined above and R 0 is hydrogen or is as defined above for R′′′, or R′′′ and R 0 , together with the nitrogen to which they are bonded, form a group selected from pyrrolidino, piperidino and morpholino groups;
- a group CONR′′′R 0 in which R′′′ is as defined above and R 0 is hydrogen or is as defined above for R′′′, or R′′′ and R 0 , together with the nitrogen to which they are bonded, form a group selected from pyrrolidino, piperidino and morpholino groups;
- a group SO 2 NR′′′R 0 in which R′′′ is as defined above and R 0 is hydrogen or is as defined above for R′′′, or R′′′ and R 0 , together with the nitrogen to which they are bonded, form a group selected from pyrrolidino, piperidino and morpholino groups;
- R′′ is hydrogen; a halogen; a (C 1 -C 6 )alkyl; a functional group as defined above; a group OR′′′, R′′′ being as defined above; a group COOR′′′, R′′′ being as defined above; or a group CONR′′′R 0 , in which R′′′ is as defined above and R 0 is hydrogen or is as defined above for R′′′, or R′′′ and R 0 , together with the nitrogen to which they are bonded, form a group selected from pyrrolidino, piperidino and morpholino groups;
- W is a direct bond or an oxygen atom
- X′ is hydrogen, a (C 1 -C 6 )alkyl or a (C 1 -C 6 )alkylcarbonyl;
- Y is hydrogen or a group A′—CH(OH)—CH 2 —, A′ being identical to A but other than benzofuran-2-yl; or
- X′ and Y taken together, form a methylene group optionally substituted by an alkoxycarbonyl in which the alkoxy is (C 1 -C6); an ethylene group optionally substituted by an oxo group; or a 1,3-propylene group;
- Z is hydrogen or a (C 1 -C 6 )alkyl
- ⁇ 3 -agonists which can also be used according to the present invention are the compounds of the formula
- E is hydrogen, a (C 1 -C 4 )alkyl, a (C 1 -C 4 )alkoxy, a phenyl, a nitro, a halogen atom or a trifluoromethyl;
- L is hydrogen, a (C 1 -C 4 )alkyl, a (C 1 -C 4 )alkoxy, a phenyl, a nitro or a halogen atom; or E and L together are a group —CH ⁇ CH—CH ⁇ CH— or —CH 2 —CH 2 —CH 2 —CH 2 —; and
- G is hydrogen, a chlorine atom, a hydroxyl or a group OG′, in which G′ is a (C 1 -C 4 )alkyl which is unsubstituted or substituted by a hydroxyl, (C 1 -C 4 )alkoxy, (C 1 -C 4 )alkoxycarbonyl, carboxyl or (C 3 -C 7 )cycloalkyl; a (C 3 -C 7 )cycloalkyl; or a (C 2 -C 4 )alkanoyl,
- N-[(2R)-(6-hydroxy-1,2,3,4-tetrahydronaphth-2-yl)methyl]-(2R)-2-hydroxy-2-(3-chlorophenyl)ethanamine (SR 59104)
- N-[(2R)-(7-methoxy-1,2,3,4-tetrahydronaphth-2-yl)methyl]-(2R)-2-hydroxy-2-(3-chlorophenyl)ethanamine SR 59119
- their pharmaceutically acceptable salts are particularly advantageous compounds.
- ⁇ 3 -agonists are the compound BRL 35135 described in EP 23385; the compound CL 316243 described in U.S. Pat. No. 5 061 727; the compound AZ 002 described in EP 218440; the compound BMS 187257 described in U.S. Pat. No. 5,321,036; the compound ZD 7114 described in EP 473 285; the compound RO 40-2148 described in Am. J. Clin.
- a CB 1 receptor antagonist compound for its use as a drug, a CB 1 receptor antagonist compound, by itself or in association with a ⁇ 3 -agonist, must be formulated as a pharmaceutical composition.
- the active principle by itself or in association with another active principle, can be administered to animals and humans in unit forms of administration mixed with conventional pharmaceutical carriers.
- the appropriate unit forms of administration include oral forms such as tablets, gelatin capsules, powders, granules and solutions or suspensions to be taken orally, sublingual and buccal forms of administration, aerosols, implants, subcutaneous, intramuscular, intravenous, intranasal or intraocular forms of administration and rectal forms of administration.
- the active principle or active principles are generally formulated in dosage units.
- the dosage unit contains from 0.5 to 1000 mg, advantageously from 1 to 500 mg and preferably from 2 to 200 mg of CB 1 receptor antagonist per dosage unit for daily administration.
- the dosage unit contains from 0.5 to 600 mg, advantageously from 1 to 400 mg and preferably from 2 to 200 mg of CB 1 receptor antagonist compound and from 0.5 to 600 mg, advantageously from 2 to 400 mg and preferably from 10 to 250 mg of the other active principle, especially a ⁇ 3-agonist.
- a wetting agent such as sodium laurylsulfate can be added to the micronized or non-micronized active principle(s) and the whole is mixed with a pharmaceutical vehicle such as silica, starch, lactose, magnesium stearate, talcum or the like.
- a pharmaceutical vehicle such as silica, starch, lactose, magnesium stearate, talcum or the like.
- the tablets can be coated with sucrose, a variety of polymers or other appropriate substances, or else they can be treated so as to have a sustained or delayed activity and so as to release a predetermined amount of active principle continuously.
- a preparation in the form of gelatin capsules is obtained by mixing the active principle or active principles with a diluent, such as a glycol or a glycerol ester, and incorporating the resulting mixture into soft or hard gelatin capsules.
- a diluent such as a glycol or a glycerol ester
- a preparation in the form of a syrup or elixir can contain the active principle or active principles together with a sweetener, which is preferably calorie-free, methylparaben and propylparaben as antiseptics, a flavoring and an appropriate color.
- a sweetener which is preferably calorie-free, methylparaben and propylparaben as antiseptics, a flavoring and an appropriate color.
- the water-dispersible powders or granules can contain the active principle or active principles mixed with dispersants or wetting agents or with suspending agents such as polyvinylpyrrolidone or polyvidone, as well as with sweeteners or taste correctors.
- Rectal administration is effected using suppositories, which are prepared with binders melting at the rectal temperature, for example cocoa butter or polyethylene glycols.
- Parenteral administration is effected using aqueous suspensions, isotonic saline solutions or injectable sterile solutions containing pharmacologically compatible dispersants and/or solubilizing agents, for example propylene glycol or butylene glycol.
- pharmacologically compatible dispersants and/or solubilizing agents for example propylene glycol or butylene glycol.
- a cosolvent for example an alcohol such as ethanol or a glycol such as polyethylene glycol or propylene glycol, and a hydrophilic surfactant such as Tween® 80.
- the active principle can be solubilized with a triglyceride or a glycerol ester.
- Transdermal administration can be effected using patches in multilaminar form or with a reservoir in which the active principle is in alcoholic solution.
- the active principle or active principles can also be formulated as microcapsules or microspheres, optionally with one or more carriers or additives.
- the active principle or active principles can also be presented in the form of complexes with a cyclodextrin, for example ⁇ -, ⁇ - or ⁇ -cyclodextrin, 2-hydroxypropyl- ⁇ -cyclodextrin or methyl- ⁇ -cyclodextrin.
- a cyclodextrin for example ⁇ -, ⁇ - or ⁇ -cyclodextrin, 2-hydroxypropyl- ⁇ -cyclodextrin or methyl- ⁇ -cyclodextrin.
- implants are prepared in the form of an oily suspension or in the form of a suspension of microspheres in an isotonic medium.
- the CB 1 receptor antagonist and the regulator of metabolic disorders can be administered simultaneously, sequentially or over a period of time in the treatment of appetency disorders, especially in the treatment of disorders of food behaviors.
- the invention therefore further relates to a kit for the treatment of appetency disorders by the administration, simultaneously, sequentially or over a period of time, of a CB 1 receptor antagonist and a regulator of metabolic disorders, especially a ⁇ 3 -agonist, in which kit said CB 1 receptor antagonist and said regulator of metabolic disorders, especially said ⁇ 3 -agonist, are in separate compartments and optionally in different packagings.
- said kit contains N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide, one of its pharmaceutically acceptable salts or one of their solvates, and N-[(2S)-7-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphth-2-yl]-(2R)-2-(3-chlorophenyl)-2-hydroxyethanamine or one of its pharmaceutically acceptable salts.
- the invention further relates to a method of treating appetency disorders, especially a method of treating disorders of food behaviors, which consists in administering, to a subject in need thereof, a (therapeutically) effective amount of a CB 1 receptor antagonist as defined above.
- Said CB 1 receptor antagonist can advantageously be used in association with a regulator of metabolic disorders, especially a ⁇ 3 agonist, as defined above.
- the CB 1 receptor antagonist and the regulator of metabolic disorders can be administered simultaneously, sequentially or over a period of time.
- Test No. 1 Effect of SR 141716 A on the Intake of a Sucrose Solution in Rats
- Test No. 2 Effect of SR 141716 A on the Consumption of an Alcohol Solution in Mice
- mice Male C 57 BL 6 mice (Iffa-Credo) are isolated on the day of their arrival in an animal housing under a reverse cycle (night from 10 am to 10 pm) with 2 bottles filled with water. After 1 week, one of the bottles of water is replaced with a bottle filled with a 10% alcohol solution for 6 hours of the test. Each day, 30 minutes before the bottle of alcohol is introduced, the mice are treated subcutaneously with SR 141716 A. The amounts of alcohol and water consumed are measured after 6 hours. The test is repeated for 4 days.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The invention relates to the use of a central cannabinoid receptor antagonist, by itself or in association with a compound for regulating metabolic disorders, especially a β3-adrenergic receptor agonist, for the preparation of drugs useful in the treatment of appetency disorders.
Description
- The present invention relates to a novel use of antagonists of the central cannabinoid receptors or so-called CB1 receptors.
- More particularly, the invention relates to the use of CB1 receptor antagonists for the preparation of drugs useful in the treatment of appetency disorders. The purpose of drugs useful in the treatment of appetency disorders is to regulate consumption desires, particularly desires to consume sugars, carbohydrates, alcohol or drugs and more generally to consume appetizing ingredients.
- In the present description and in the claims, appetency disorders are understood as meaning:
- disorders associated with a substance and especially abuse of a substance and/or dependency on a substance,
- disorders of food behaviors, especially those liable to cause excess weight, irrespective of its origin, for example: bulimia, appetency for sugars, non-insulin-dependent diabetes.
- Substances are understood as meaning appetizing ingredients such as sugars, carbohydrates, alcohols or drugs.
- The present invention therefore further relates to the use of a CB1 receptor antagonist for the preparation of drugs useful in the treatment of bulimia and obesity, including obesity associated with type II diabetes (non-insulin-dependent diabetes), or more generally any disease resulting in the patient becoming overweight, and in the treatment of drug abuse or drug dependency.
- Delta-9-tetrahydrocannabinol, or Δ9-THC, is the main active constituent extracted from Cannabis sativa (Tuner, 1985; in Marijuana, 84, Ed. Harvey, D Y, IRL Press, Oxford).
- The effects of cannabinoids are due to an interaction with high affinity specific receptors coupled to G proteins. Two types of receptors are currently described: the CB1 receptors, which are present predominantly in the central nervous system (Devane et al., Molecular Pharmacology, 1988, 34, 605-613), and the CB2 receptors, which are present in the immune system (Nye et al., The Journal of Pharmacology and Experimental Therapeutics, 1985, 234, 784-791; Kaminski et al., 1992, Molecular Pharmacology, 42, 736-742; Munro et al., Nature, 1993, 365, 61-65). Characterization of these receptors has been made possible by the development of synthetic ligands such as CP 55,940 (J. Pharmacol. Exp. Ther., 1988, 247, 1046-1051) and WIN 55212-2 (J. Pharmacol. Exp. Ther., 1993, 264, 1352-1363) and, more recently, by the discovery of the selective CB1 receptor antagonist SR 141716 A (M. Rinaldi-Carmona et al., FEBS Lett., 1994, 350, 240-244).
- Families of compounds having an affinity for the cannabinoid receptors have been described in several patents or patent applications, especially European patent application EP-576 357, which describes pyrazole derivatives, and patent application WO 96/02248, which describes especially benzofuran derivatives.
-
- its pharmaceutically acceptable salts and their solvates are described in European patent application EP-656 354 as CB1 central receptor antagonists.
- SR 141716 A is the hydrochloride of SR 141716.
- It is known that delta-9-tetrahydrocannabinol, whose international non-proprietary name is Dronabinol, is used in the treatment of anorexia, especially in patients suffering from AIDS (J. Pain Symptom Manage., 1995, 10 (2), 89-97) or cancer (J. Palliat. Care, 1994, 10 (1), 14-18).
- It is further described that SR 141716 and its salts, which are central cannabinoid receptor antagonists, can be used in the treatment of appetite disorders, especially as anorexigenic agents, and in the treatment of disorders associated with the use of psychotropic substances.
- Conventional anorexigenic agents cause an appetite reduction which is generally independent of the foods to be consumed.
- Surprisingly, it has now been found that CB1 receptor antagonists have a specific property by acting electively on consumption behavior disorders pertaining to appetizing substances.
- Thus the administration of a CB1 receptor antagonist makes it possible to regulate the desire to consume non-essential food items such as excess sugars, excess carbohydrates, alcohol or drugs.
- In fact, after having conducted tests in animals, a novel behavior of the animal has been noted: animal tests have revealed a novel behavior: the animal no longer shows spontaneous appetency for the ingredient, for example sugar or alcohol, which usually brings pleasure to it. This lack of appetency also manifests itself when the animal has been pretreated with a neuropeptide known to increase the appetite, for example neuropeptide Y (NPY).
- According to one of its aspects, the present invention relates to the use of a CB1 receptor antagonist for the preparation of drugs useful in the treatment of appetency disorders.
-
- in which:
- R1 is hydrogen, a fluorine, a hydroxyl, a (C1-C5)alkoxy, a (C1-C5)alkylthio, a hydroxy(C1-C5)alkoxy, a group —NR10R11, a cyano, a (C1-C5)alkylsulfonyl or a (C1-C5)alkylsulfinyl;
- R2 and R3 are a (C1-C4)alkyl or, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated 5- to 10-membered heterocyclic radical which is unsubstituted or monosubstituted or polysubstituted by a (C1-C3)alkyl or by a (C1-C3)alkoxy;
- R4, R5, R6, R7, R8 and R9 are each independently hydrogen, a halogen or a trifluoromethyl, and if R1 is a fluorine, R4, R5, R6, R7, R8 and/or R9 can also be a fluoromethyl, with the proviso that at least one of the substituents R4 or R7 is other than hydrogen; and
- R10 and R11, are each independently hydrogen or a (C1-C5)alkyl, or R10, and R11, together with the nitrogen atom to which they are bonded, form a heterocyclic radical selected from pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl and piperazin-1-yl, which is unsubstituted or substituted by a (C1-C4)alkyl,
- and their salts and their solvates.
- More particularly, the present invention relates to the use of N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide, its pharmaceutically acceptable salts and their solvates for the preparation of drugs useful in the treatment of appetency disorders.
- According to the present invention, the CB1 receptor antagonists can also be used in association with another active principle for the preparation of drugs useful in the treatment of appetency disorders, especially in the treatment of disorders of food behaviors; it is possible to use a pharmaceutical composition comprising a CB1 receptor antagonist in association with a compound for regulating metabolic disorders, especially a β3-adrenergic receptor agonist, hereafter called a β3-agonist.
- Thus the present invention further relates to pharmaceutical compositions containing a CB1 receptor antagonist and a regulator of metabolic disorders, for example a hypolipemic, hypolydemic or lipolytic. More particularly, the present invention relates to pharmaceutical compositions containing a CB1 receptor antagonist and a β3-agonist.
-
- in which:
- X is hydrogen, a halogen, a trifluoromethyl or a (C1-C4)alkyl;
- R is hydrogen or a methyl which is unsubstituted or substituted by a carboxyl or an alkoxycarbonyl in which the alkoxy is (C1-C6),
- and their pharmaceutically acceptable salts, indicated in EP 0 211 721 and EP 0 303 546 as intestinal spasmolytics.
- Among the compounds of formula (III), the following compounds:
- 2-[(7-hydroxy-1,2,3,4-tetrahydronaphth-2-yl)amino]-1-phenylethanol;
- 2-[(7-hydroxy-1,2,3,4-tetrahydronaphth-2-yl)amino]-1-(3-chlorophenyl)-ethanol;
- 2-[(7-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphth-2-yl)amino]-1-(3-chlorophenyl)ethanol;
- 2-[(7-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphth-2-yl)amino]-1-phenylethanol;
- (1R,2′RS)-2-[(7-hydroxy-1,2,3,4-tetrahydronaphth-2-yl)amino]-1-phenylethanol;
- (1S,2′RS)-2-[(7-hydroxy-1,2,3,4-tetrahydronaphth-2-yl)amino]-1-phenylethanol;
- (+)-(1R)-2-[(7-hydroxy-1,2,3,4-tetrahydronaphth-2-yl)amino]-1-phenylethanol;
- (+)-(1S)-2-[(7-hydroxy-1,2,3,4-tetrahydronaphth-2-yl)amino]-1-phenylethanol;
- (−)-(1R)-2-[(7-hydroxy-1,2,3,4-tetrahydronaphth-2-yl)amino]-1-phenylethanol;
- (−)-(1S)-2-[(7-hydroxy-1,2,3,4-tetrahydronaphth-2-yl)amino]-1-phenylethanol;
- N-[(2S)-7-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphth-2-yl]-(2R)-2-(3-chlorophenyl)-2-hydroxyethanamine; and
- N-[(2R)-7-methoxycarbonylmethoxy-1,2,3,4-tetrahydronaphth-2-yl]-(2R)-2-(3-chlorophenyl)-2-hydroxyethanamine,
- and their pharmaceutically acceptable salts, are particularly advantageous.
- N-[(2S)-7-Ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphth-2-yl]-(2R)-2-(3-chlorophenyl)-2-hydroxyethanamine (SR 58611) and its pharmaceutically acceptable salts are very particularly advantageous, especially its salt with hydrochloric acid, SR 58611 A.
-
- in which:
- n is 1,2 or 3;
- A is a benzofuran-2-yl or a phenyl which is unsubstituted or substituted by one or two halogen atoms or by a (C1-C4)alkyl or a trifluoromethyl;
- R′ is:
- hydrogen;
- a (C1-C6)alkyl;
- a functional group selected from the following groups: hydroxyl; (C1-C6)alkoxy; (C2-C6)alkenyloxy; (C2-C6)alkynyloxy; (C3-C8)cycloalkoxy; (C3-C8)cycloalkyl(C1-C6)alkoxy; benzyloxy; phenoxy; mercapto; (C1-C6)alkylthio; (C2-C6)alkenylthio; (C2-C6)alkynylthio; (C3-C8)cycloalkylthio; (C3 -C8)cycloalkyl(C1-C6)alkylthio; benzylthio; phenylthio; (C1-C6)alkylsulfinyl; (C2-C6)alkenylsulfinyl; (C2-C6)alkynylsulfinyl; (C3-C8)cycloalkylsulfinyl; (C3-C8)cycloalkyl(C1-C6)alkylsulfinyl; benzylsulfinyl; phenylsulfinyl; (C1-C6)alkylsulfonyl; (C2-C6)alkenylsulfonyl; (C2-C6)alkynylsulfonyl; (C3-C8)cycloalkylsulfonyl; (C3-C8)cycloalkyl(C1-C6)alkylsulfonyl; benzylsulfonyl; phenylsulfonyl; cyano; nitro; amino which is unsubstituted or substituted by one or two identical or different radicals selected from (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(C1-C6)alkyl, benzyl and phenyl groups; carboxyl; alkoxycarbonyl in which the alkoxy is (C1-C6); (C2-C6)alkenyloxycarbonyl; (C2-C6)alkenyloxycarbonyl; (C3-C8)cycloalkoxycarbonyl; (C3-C8)cycloalkyl(C1-C6)alkoxycarbonyl; benzyloxycarbonyl; phenoxycarbonyl; or carbamoyl which is unsubstituted or substituted on the amino group by one or two identical or different radicals selected from (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(C1-C6)alkyl, benzyl and phenyl groups;
- a group R′″ selected from the following groups: (C1-C6)alkyl substituted by a functional group; (C2-C6)alkenyl substituted by a functional group; (C2-C6)alkynyl substituted by a functional group; phenyl(C1-C6)alkyl substituted on the phenyl by a (C1-C6)alkyl or by a functional group; phenyl(C2-C6)alkenyl substituted on the phenyl by a (C1-C6)alkyl or by a functional group; phenyl(C2-C6)alkynyl substituted on the phenyl by a (C1-C6)alkyl or by a functional group; benzyl substituted on the phenyl by a (C1-C6)alkyl or by a functional group; and phenyl which is unsubstituted or substituted by a (C1-C6)alkyl or by a functional group, the functional group being as defined above;
- a group O—R′″, S—R′″, SO—R′″ or SO2—R′″, in which R′″ is as defined above;
- a group NR′″R0, in which R′″ is as defined above and R0 is hydrogen or is as defined above for R′″, or R′″ and R0, together with the nitrogen to which they are bonded, form a group selected from pyrrolidino, piperidino and morpholino groups;
- a group COOR′″ or a group CO—SR′″, in which R′″ is as defined above;
- a group CONR′″R0, in which R′″ is as defined above and R0 is hydrogen or is as defined above for R′″, or R′″ and R0, together with the nitrogen to which they are bonded, form a group selected from pyrrolidino, piperidino and morpholino groups;
- a group SO2NR′″R0, in which R′″ is as defined above and R0 is hydrogen or is as defined above for R′″, or R′″ and R0, together with the nitrogen to which they are bonded, form a group selected from pyrrolidino, piperidino and morpholino groups;
- R″ is hydrogen; a halogen; a (C1-C6)alkyl; a functional group as defined above; a group OR′″, R′″ being as defined above; a group COOR′″, R′″ being as defined above; or a group CONR′″R0, in which R′″ is as defined above and R0 is hydrogen or is as defined above for R′″, or R′″ and R0, together with the nitrogen to which they are bonded, form a group selected from pyrrolidino, piperidino and morpholino groups;
- W is a direct bond or an oxygen atom;
- X′ is hydrogen, a (C1-C6)alkyl or a (C1-C6)alkylcarbonyl;
- Y is hydrogen or a group A′—CH(OH)—CH2—, A′ being identical to A but other than benzofuran-2-yl; or
- X′ and Y, taken together, form a methylene group optionally substituted by an alkoxycarbonyl in which the alkoxy is (C1-C6); an ethylene group optionally substituted by an oxo group; or a 1,3-propylene group;
- Z is hydrogen or a (C1-C6)alkyl,
- and their pharmaceutically acceptable salts, indicated in EP 0 255 415 as intestinal spasmolytics.
-
- in which:
- E is hydrogen, a (C1-C4)alkyl, a (C1-C4)alkoxy, a phenyl, a nitro, a halogen atom or a trifluoromethyl;
- L is hydrogen, a (C1-C4)alkyl, a (C1-C4)alkoxy, a phenyl, a nitro or a halogen atom; or E and L together are a group —CH═CH—CH═CH— or —CH2—CH2—CH2—CH2—; and
- G is hydrogen, a chlorine atom, a hydroxyl or a group OG′, in which G′ is a (C1-C4)alkyl which is unsubstituted or substituted by a hydroxyl, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, carboxyl or (C3-C7)cycloalkyl; a (C3-C7)cycloalkyl; or a (C2-C4)alkanoyl,
- and their pharmaceutically acceptable salts, indicated in EP 0 436 435 as intestinal spasmolytics.
- Among the compounds of formula (V), N-[(2R)-(6-hydroxy-1,2,3,4-tetrahydronaphth-2-yl)methyl]-(2R)-2-hydroxy-2-(3-chlorophenyl)ethanamine (SR 59104), N-[(2R)-(7-methoxy-1,2,3,4-tetrahydronaphth-2-yl)methyl]-(2R)-2-hydroxy-2-(3-chlorophenyl)ethanamine (SR 59119) and their pharmaceutically acceptable salts are particularly advantageous compounds.
- Other advantageous β3-agonists according to the present invention are the compound BRL 35135 described in EP 23385; the compound CL 316243 described in U.S. Pat. No. 5 061 727; the compound AZ 002 described in EP 218440; the compound BMS 187257 described in U.S. Pat. No. 5,321,036; the compound ZD 7114 described in EP 473 285; the compound RO 40-2148 described in Am. J. Clin. Nutr., 1992, 55 (1, Suppl.), 249S-251S; and the products described in the following patents/patent applications: WO 96/35671, WO 96/35670, WO 96/16038, WO 96/04233, WO 95/33724, WO 95/29159, EP 659737, WO 95/04047, EP 516349, EP 473285, EP 23385, EP 21636, EP 7205, JP 08198866, JP 08165276, JP 08157470, WO 96/16938, EP 714883, WO 96/04234, U.S. Pat. Nos. 5,488,064, 5,482,971, 5,491,134, WO 95/29159, WO 95/33724, ZA 9409874, WO 95/29903, U.S. Pat. No. 5,461,163, WO 95/25104, EP 659737, JP 07112958, WO 95/8527, WO 95/07284, JP 07025756, WO 95/03289, WO 95/04047, WO 95/01170, WO 94/29290, U.S. Pat. No. 5,373,020, JP 06293664, WO 94/12166 and U.S. Pat. No. 5,451,677.
- For its use as a drug, a CB1 receptor antagonist compound, by itself or in association with a β3-agonist, must be formulated as a pharmaceutical composition.
- In the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, transdermal, local or rectal administration, the active principle, by itself or in association with another active principle, can be administered to animals and humans in unit forms of administration mixed with conventional pharmaceutical carriers. The appropriate unit forms of administration include oral forms such as tablets, gelatin capsules, powders, granules and solutions or suspensions to be taken orally, sublingual and buccal forms of administration, aerosols, implants, subcutaneous, intramuscular, intravenous, intranasal or intraocular forms of administration and rectal forms of administration.
- In the pharmaceutical compositions of the present invention, the active principle or active principles are generally formulated in dosage units. The dosage unit contains from 0.5 to 1000 mg, advantageously from 1 to 500 mg and preferably from 2 to 200 mg of CB1 receptor antagonist per dosage unit for daily administration.
- In cases where 2 active principles are associated, the dosage unit contains from 0.5 to 600 mg, advantageously from 1 to 400 mg and preferably from 2 to 200 mg of CB1 receptor antagonist compound and from 0.5 to 600 mg, advantageously from 2 to 400 mg and preferably from 10 to 250 mg of the other active principle, especially a β3-agonist.
- When a solid composition is prepared in the form of tablets, a wetting agent such as sodium laurylsulfate can be added to the micronized or non-micronized active principle(s) and the whole is mixed with a pharmaceutical vehicle such as silica, starch, lactose, magnesium stearate, talcum or the like. The tablets can be coated with sucrose, a variety of polymers or other appropriate substances, or else they can be treated so as to have a sustained or delayed activity and so as to release a predetermined amount of active principle continuously.
- A preparation in the form of gelatin capsules is obtained by mixing the active principle or active principles with a diluent, such as a glycol or a glycerol ester, and incorporating the resulting mixture into soft or hard gelatin capsules.
- A preparation in the form of a syrup or elixir can contain the active principle or active principles together with a sweetener, which is preferably calorie-free, methylparaben and propylparaben as antiseptics, a flavoring and an appropriate color.
- The water-dispersible powders or granules can contain the active principle or active principles mixed with dispersants or wetting agents or with suspending agents such as polyvinylpyrrolidone or polyvidone, as well as with sweeteners or taste correctors.
- Rectal administration is effected using suppositories, which are prepared with binders melting at the rectal temperature, for example cocoa butter or polyethylene glycols.
- Parenteral administration is effected using aqueous suspensions, isotonic saline solutions or injectable sterile solutions containing pharmacologically compatible dispersants and/or solubilizing agents, for example propylene glycol or butylene glycol.
- Thus, to prepare an aqueous solution for intravenous injection, it is possible to use a cosolvent, for example an alcohol such as ethanol or a glycol such as polyethylene glycol or propylene glycol, and a hydrophilic surfactant such as Tween® 80. To prepare an oily solution for intramuscular injection, the active principle can be solubilized with a triglyceride or a glycerol ester.
- Transdermal administration can be effected using patches in multilaminar form or with a reservoir in which the active principle is in alcoholic solution.
- The active principle or active principles can also be formulated as microcapsules or microspheres, optionally with one or more carriers or additives.
- The active principle or active principles can also be presented in the form of complexes with a cyclodextrin, for example α-, β- or γ-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin or methyl-β-cyclodextrin.
- Among the sustained release forms useful in the case of chronic treatments, it is possible to use implants. These can be prepared in the form of an oily suspension or in the form of a suspension of microspheres in an isotonic medium.
- According to another aspect of the invention, the CB1 receptor antagonist and the regulator of metabolic disorders, especially the β3-agonist, can be administered simultaneously, sequentially or over a period of time in the treatment of appetency disorders, especially in the treatment of disorders of food behaviors.
- The invention therefore further relates to a kit for the treatment of appetency disorders by the administration, simultaneously, sequentially or over a period of time, of a CB1 receptor antagonist and a regulator of metabolic disorders, especially a β3-agonist, in which kit said CB1 receptor antagonist and said regulator of metabolic disorders, especially said β3-agonist, are in separate compartments and optionally in different packagings.
- More particularly, said kit contains N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide, one of its pharmaceutically acceptable salts or one of their solvates, and N-[(2S)-7-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphth-2-yl]-(2R)-2-(3-chlorophenyl)-2-hydroxyethanamine or one of its pharmaceutically acceptable salts.
- According to another of its aspects, the invention further relates to a method of treating appetency disorders, especially a method of treating disorders of food behaviors, which consists in administering, to a subject in need thereof, a (therapeutically) effective amount of a CB1 receptor antagonist as defined above. Said CB1 receptor antagonist can advantageously be used in association with a regulator of metabolic disorders, especially a β3 agonist, as defined above. In particular, the CB1 receptor antagonist and the regulator of metabolic disorders can be administered simultaneously, sequentially or over a period of time.
- Test No. 1: Effect of SR 141716 A on the Intake of a Sucrose Solution in Rats
- The experiment is performed according to W. C. Lynch et al., Physiol. Behav., 1993, 54, 877-880.
- Male Sprague-Dawley rats weighing 190 to 210 g are under a normal light cycle (from 7 am to 7 pm) and receive water and food ad libitum.
- For 6 days, between 11 am and 3 pm, the food and the water bottles are withdrawn and the rats are given a 5% sucrose solution to drink.
- Rats drinking less than 3 g of sucrose solution are eliminated.
- On the seventh day the test is carried out according to the following procedure:
- 9 am: withdrawal of food,
- 10 am: oral administration of SR 141716 A,
- 11 am =T0: introduction of bottles containing a weighed sucrose solution, T0+1 hour, T0+2 hours, T0+3 hours, T0+4 hours: measurement of the sucrose consumption by weighing of the bottles.
TABLE 1 Treatment Number of Consumption of sucrose solution in g po rats 1 hour 2 hours 3 hours 4 hours Vehicle 8 11.33 ± 17.74 ± 22.50 ± 28.34 ± 2 ml/kg 2.50 4.00 4.83 5.01 SR 141716 A 6 5.18 ± 9.18 ± 12.49 ± 16.10 ± 0.3 mg/kg 1.61 2.12 4.47 3.95 SR 141716 A 6 3.27* ± 3.61** ± 5.65* ± 7.43** ± 1 mg/kg 1.40 1.40 2.23 2.81 SR 141716 A 6 2.95* ± 5.41* ± 6.96* ± 8.58** ± 3 mg/kg 1.20 1.33 2.15 2.92 - It is seen from the results reported in TABLE 1 that the administration of SR 141716 A very considerably reduces the consumption of aqueous sugar solution at or above a dose of 0.3 mg/kg.
- Test No. 2: Effect of SR 141716 A on the Consumption of an Alcohol Solution in Mice
- Male C 57 BL 6 mice (Iffa-Credo) are isolated on the day of their arrival in an animal housing under a reverse cycle (night from 10 am to 10 pm) with 2 bottles filled with water. After 1 week, one of the bottles of water is replaced with a bottle filled with a 10% alcohol solution for 6 hours of the test. Each day, 30 minutes before the bottle of alcohol is introduced, the mice are treated subcutaneously with SR 141716 A. The amounts of alcohol and water consumed are measured after 6 hours. The test is repeated for 4 days.
TABLE 2 Amount of Treatment mg/kg/sc Number of Amount of alcohol water SR 141716 A mice consumed in g on D4 consumed in g Vehicle 20 1.9 ± 0.1 1.1 ± 0.1 0.1 10 1.4 ± 0.2 1.1 ± 0.3 0.3 10 1.3 ± 0.2 1.1 ± 0.3 1 10 1.1 ± 0.2** 1.3 ± 0.1 3 10 1.0 ± 0.2** 1.6 ± 0.3 - The results show that the alcohol consumption decreases very substantially for the treated animals: from 1.9±0.1 g for an untreated animal to 1.0±0.2 g for an animal receiving 3 mg/kg of SR 141716 A; the water consumption increased in parallel: from 1.1±0.1 to 1.6±0.3 g.
- Gelatin Capsule Containing a 1 mg Dose of CB1 Receptor Antagonist
Micronized SR 141716 1.00 mg Corn starch 51.00 mg Lactose monohydrate 103.33 mg Polyvidone 4.30 mg Sodium laurylsulfate 0.17 mg Crosslinked sodium carboxymethyl cellulose 8.50 mg Purified water: QS for wet granulation Magnesium stearate 1.70 mg - For a no. 3 opaque white gelatin capsule filled to 170 mg.
- Gelatin Capsule Containing a 10 mg Dose of CB1 Receptor Antagonist
Micronized SR 141716 A 10.00 mg Corn starch 51.00 mg Lactose monohydrate 94.33 mg Polyvidone 4.30 mg Sodium laurylsulfate 0.17 mg Crosslinked sodium carboxymethyl cellulose 8.50 mg Purified water: QS for wet granulation Magnesium stearate 1.70 mg - For a no. 3 opaque white gelatin capsule filled to 170 mg.
- Gelatin Capsule Containing a 30 mg Dose of CB1 Receptor Antagonist
Micronized SR 141716 30.00 mg Corn starch 51.00 mg Lactose monohydrate 74.33 mg Polyvidone 4.30 mg Sodium laurylsulfate 0.17 mg Crosslinked sodium carboxymethyl cellulose 8.50 mg Purified water: QS for wet granulation Magnesium stearate 1.70 mg - For a no. 3 opaque white gelatin capsule filled to 170 mg.
- Tablet Containing a 30 mg Dose of CB1 Receptor Antagonist
Micronized SR 141716 30.00 mg Lactose monohydrate QS Corn starch 40.00 mg Hydroxypropyl methyl cellulose 6 cP 5.00 mg Purified water: QS for wet granulation Crosslinked sodium carboxymethyl cellulose 10.00 mg Magnesium stearate 2.00 mg - For a finished tablet of 200 mg.
- Tablet Containing 30 mg of CB1 Receptor Antagonist and 200 mg of β3-Agonist
Micronized SR 141716 30.00 mg SR 58611 A expressed as the base 200.00 mg Lactose monohydrate QS Polyvidone 15.00 mg Purified water: QS for wet granulation Crosslinked sodium carboxymethyl cellulose 10.00 mg Magnesium stearate 5.00 mg - For a finished tablet of 500 mg.
- Tablet Containing 10 mg of CB1 Receptor Antagonist and 100 mg of β3-Agonist
Micronized SR 141716 10.00 mg SR 58611 A expressed as the base 100.00 mg Corn starch 30 mg Lactose monohydrate QS Hydroxypropyl methyl cellulose 6 cP 5.00 mg Purified water: QS for wet granulation Sodium carboxymethyl starch 6.00 mg Magnesium stearate 3.00 mg - For a finished tablet of 300 mg.
Claims (38)
1. Use of a CB1 receptor antagonist for the preparation of drugs useful in the treatment of appetency disorders.
2. Use according to claim 1 for the preparation of drugs intended for regulating consumption desires.
3. Use according to claim 1 for the preparation of drugs useful in the treatment of disorders associated with a substance.
4. Use according to claim 1 for the preparation of drugs useful in the treatment of disorders of food behaviors.
5. Use according to claim 1 for the preparation of drugs useful in the treatment of obesity.
6. Use according to claim 5 for the preparation of drugs useful in the treatment of obesity associated with non-insulin-dependent diabetes.
7. Use according to claim 1 for the preparation of drugs useful in the treatment of any disease resulting in the patient becoming overweight.
8. Use according to claim 1 for the preparation of drugs useful in the treatment of bulimia.
9. Use according to claim 1 for the preparation of drugs useful in the treatment of drug abuse or drug dependency.
10. Use according to any one of claims 1 to 9 , characterized in that the CB1 receptor antagonist is a compound of the formula
in which:
R1 is hydrogen, a fluorine, a hydroxyl, a (C1-C5)alkoxy, a (C1-C5)alkylthio, a hydroxy(C1-C5)alkoxy, a group —NR10R11, a cyano, a (C1-C5)alkylsulfonyl or a (C1-C5)alkylsulfinyl;
R2 and R3 are a (C1-C4)alkyl or, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated 5- to 10-membered heterocyclic radical which is unsubstituted or monosubstituted or polysubstituted by a (C1-C3)alkyl or by a (C1-C3)alkoxy;
R4, R5, R6, R7, R8 and R9 are each independently hydrogen, a halogen or a trifluoromethyl, and if R1 is a fluorine, R4, R5, R6, R7, R8 and/or R9 can also be a fluoromethyl, with the proviso that at least one of the substituents R4 or R7 is other than hydrogen;
R10 and R11 are each independently hydrogen or a (C1-C5)alkyl, or R10 and R11, together with the nitrogen atom to which they are bonded, form a heterocyclic radical selected from pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl and piperazin-1-yl, which is unsubstituted or substituted by a (C1-C4)alkyl, one of its salts or one of their solvates.
11. Use according to claim 10 , characterized in that the CB1 receptor antagonist is N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide, one of its pharmaceutically acceptable salts or one of their solvates.
12. Use according to any one of claims 1 to 8 , 10 or 11, characterized in that the CB1 receptor antagonist is associated with a regulator of metabolic disorders.
13. Use according to claim 12 , characterized in that said regulator of metabolic disorders is a β3-agonist.
14. Use according to claim 13 , characterized in that said β3-agonist is a compound of the formula
in which:
X is hydrogen, a halogen, a trifluoromethyl or a (C1-C4)alkyl; and
R is hydrogen or a methyl which is unsubstituted or substituted by a carboxyl or an alkoxycarbonyl in which the alkoxy is (C1-C6), or one of its pharmaceutically acceptable salts.
15. Use according to claim 14 , characterized in that said β3-agonist is N-[(2S)-7-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphth-2-yl]-(2R)-2-(3-chlorophenyl)-2-hydroxyethanamine or one of its pharmaceutically acceptable salts.
16. Use according to claim 13 , characterized in that said β3-agonist is a compound of the formula
in which:
n is 1,2 or 3;
A is a benzofuran-2-yl or a phenyl which is unsubstituted or substituted by one or two halogen atoms or by a (C1-C4)alkyl or a trifluoromethyl;
R′ is:
hydrogen;
a (C1-C6)alkyl;
a functional group selected from the following groups: hydroxyl; (C1-C6)alkoxy; (C2-C6)alkenyloxy; (C2-C6)alkynyloxy; (C3-C8)cycloalkoxy; (C3-C8)cycloalkyl(C1-C6)alkoxy; benzyloxy; phenoxy; mercapto; (C1-C6)alkylthio; (C2-C6)alkenylthio; (C2-C6)alkynylthio; (C3-C8)cycloalkylthio; (C3-C8)cycloalkyl(C1-C6)alkylthio; benzylthio; phenylthio; (C1-C6)alkylsulfinyl; (C2-C6)alkenylsulfinyl; (C2-C6)alkynylsulfinyl; (C3-C8)cycloalkylsulfinyl; (C3-C8)cycloalkyl(C1-C6)alkylsulfinyl; benzylsulfinyl; phenylsulfinyl; (C1-C6)alkylsulfonyl; (C2-C6)alkenylsulfonyl; (C2-C6)alkynylsulfonyl; (C3-C8)cycloalkylsulfonyl; (C3-C8)cycloalkyl(C1-C6)alkylsulfonyl; benzylsulfonyl; phenylsulfonyl; cyano; nitro; amino which is unsubstituted or substituted by one or two identical or different radicals selected from (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(C1-C6)alkyl, benzyl and phenyl groups; carboxyl; alkoxycarbonyl in which the alkoxy is (C1-C6); (C2-C6)alkynyloxycarbonyl; (C2-C6)alkenyloxycarbonyl; (C3-C8)cycloalkoxycarbonyl; (C3-C8)cycloalkyl(C1-C6)alkoxycarbonyl; benzyloxycarbonyl; phenoxycarbonyl; or carbamoyl which is unsubstituted or substituted on the amino group by one or two identical or different radicals selected from (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(C1-C6)alkyl, benzyl and phenyl groups;
a group R′″ selected from the following groups: (C1-C6)alkyl substituted by a functional group; (C2-C6)alkenyl substituted by a functional group; (C2-C6)alkynyl substituted by a functional group; phenyl(C1-C6)alkyl substituted on the phenyl by a (C1-C6)alkyl or by a functional group; phenyl(C2-C6)alkenyl substituted on the phenyl by a (C1-C6)alkyl or by a functional group; phenyl(C2-C6)alkynyl substituted on the phenyl by a (C1-C6)alkyl or by a functional group; benzyl substituted on the phenyl by a (C1-C6)alkyl or by a functional group; and phenyl which is unsubstituted or substituted by a (C1-C6)alkyl or by a functional group, the functional group being as defined above;
a group O—R′″, S—R′″, SO—R′″, or SO2—R′″, in which R′″ is as defined above;
a group NR′″R0, in which R′″ is as defined above and R0 is hydrogen or is as defined above for R′″, or R′″ and R0, together with the nitrogen to which they are bonded, form a group selected from pyrrolidino, piperidino and morpholino groups;
a group COOR′″ or a group CO—SR′″, in which R′″ is as defined above;
a group CONR′″R0, in which R′″ is as defined above and R0 is hydrogen or is as defined above for R′″, or R′″ and R0, together with the nitrogen to which they are bonded, form a group selected from pyrrolidino, piperidino and morpholino groups;
a group SO2NR′″R0, in which R′″ is as defined above and R0 is hydrogen or is as defined above for R′″, or R′″ and R0, together with the nitrogen to which they are bonded, form a group selected from pyrrolidino, piperidino and morpholino groups;
R′ is hydrogen; a halogen; a (C1-C6)alkyl; a functional group as defined above; a group OR′″, R′″ being as defined above; a group COOR′″, R′″ being as defined above; or a group CONR′″R0, in which R′″ is as defined above and R0 is hydrogen or is as defined above for R′″, or R′″ and R0, together with the nitrogen to which they are bonded, form a group selected from pyrrolidino, piperidino and morpholino groups;
W is a direct bond or an oxygen atom;
X′ is hydrogen, a (C1-C6)alkyl or a (C1-C6)alkylcarbonyl;
Y is hydrogen or a group A′—CH(OH)—CH2—, A′ being identical to A but other than benzofuran-2-yl; or
X′ and Y, taken together, form a methylene group optionally substituted by an alkoxycarbonyl in which the alkoxy is (C1-C6); an ethylene group optionally substituted by an oxo group; or a 1,3-propylene group;
Z is hydrogen or a (C1-C6)alkyl, or one of its pharmaceutically acceptable salts.
17. Use according to claim 13 , characterized in that said β3-agonist is a compound of the formula
in which:
E is hydrogen, a (C1-C4)alkyl, a (C1-C4)alkoxy, a phenyl, a nitro, a halogen atom or a trifluoromethyl;
L is hydrogen, a (C1-C4)alkyl, a (C1-C4)alkoxy, a phenyl, a nitro or a halogen atom; or E and L together are a group —CH═CH—CH═CH— or —CH2—CH2—CH2—CH2—; and
G is hydrogen, a chlorine atom, a hydroxyl or a group OG′, in which G′ is a (C1-C4)alkyl which is unsubstituted or substituted by a hydroxyl, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, carboxyl or (C3-C7)cycloalkyl; a (C3-C7)cycloalkyl; or a (C2-C4)alkanoyl, or one of its pharmaceutically acceptable salts.
18. Use according to claim 13 , characterized in that the CB1 receptor antagonist is N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide, one of its pharmaceutically acceptable salts or one of their solvates and the β3-agonist is N-[(2S)-7-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphth-2-yl]-(2R)-2-(3-chlorophenyl)-2-hydroxyethanamine or one of its pharmaceutically acceptable salts.
19. A pharmaceutical composition containing a CB1 receptor antagonist and a regulator of metabolic functions with a pharmaceutical excipient.
20. A pharmaceutical composition according to claim 19 , characterized in that said regulator of metabolic functions is a β3-agonist.
21. A pharmaceutical composition according to claim 19 or 20, characterized in that the CB1 receptor antagonist is a compound of the formula
in which:
R1 is hydrogen, a fluorine, a hydroxyl, a (C1-C5)alkoxy, a (C1-C5)alkylthio, a hydroxy(C1-C5)alkoxy, a group —NR10R11, a cyano, a (C1-C5)alkylsulfonyl or a (C1-C5)alkylsulfinyl;
R2 and R3 are a (C1-C4)alkyl or, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated 5- to 10-membered heterocyclic radical which is unsubstituted or monosubstituted or polysubstituted by a (C1-C3)alkyl or by a (C1-C3)alkoxy;
R4, R5, R6, R7, R8 and R9 are each independently hydrogen, a halogen or a trifluoromethyl, and if R1 is a fluorine, R4, R5, R6, R7, R8 and/or R9 can also be a fluoromethyl, with the proviso that at least one of the substituents R4 or R7 is other than hydrogen;
R10 and R11 are each independently hydrogen or a (C1-C5)alkyl, or R10 and R11, together with the nitrogen atom to which they are bonded, form a heterocyclic radical selected from pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl and piperazin-1-yl, which is unsubstituted or substituted by a (C1-C4)alkyl, one of its salts or one of their solvates.
22. A pharmaceutical composition according to claim 21 , characterized in that the CB1 receptor antagonist is N-piperidino-5-(4-chlorophenyl)- 1 -(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide, one of its pharmaceutically acceptable salts or one of their solvates.
23. A pharmaceutical composition according to any one of claims 20 to 22 , characterized in that the β3-agonist is a compound of the formula
in which:
X is hydrogen, a halogen, a trifluoromethyl or a (C1-C4)alkyl;
R is hydrogen or a methyl which is unsubstituted or substituted by a carboxyl or an alkoxycarbonyl in which the alkoxy is (C1-C6), or one of its pharmaceutically acceptable salts.
24. A pharmaceutical composition according to any one of claims 20 to 22 , characterized in that the β3-agonist is a compound of the formula
in which:
n is 1,2 or 3;
A is a benzofuran-2-yl or a phenyl which is unsubstituted or substituted by one or two halogen atoms or by a (C1-C4)alkyl or a trifluoromethyl;
R′ is:
hydrogen;
a (C1-C6)alkyl;
a functional group selected from the following groups: hydroxyl; (C1-C6)alkoxy; (C2-C6)alkenyloxy; (C2-C6)alkynyloxy; (C3-C8)cycloalkoxy; (C3-C8)cycloalkyl(C1-C6)alkoxy; benzyloxy; phenoxy; mercapto; (C1-C6)alkylthio; (C2-C6)alkenylthio; (C2-C6)alkynylthio; (C3-C8)cycloalkylthio; (C3-C8)cycloalkyl(C1-C6)alkylthio; benzylthio; phenylthio; (C1-C6)alkylsulfinyl; (C2-C6)alkenylsulfinyl; (C2-C6)alkynylsulfinyl; (C3-C8)cycloalkylsulfinyl; (C3-C8) cycloalkyl(C1-C6)alkylsulfinyl; benzylsulfinyl; phenylsulfinyl; (C1-C6)alkylsulfonyl; (C2-C6)alkenylsulfonyl; (C2-C6)alkynylsulfonyl; (C3-C8)cycloalkylsulfonyl; (C3-C8)cycloalkyl(C1-C6)alkylsulfonyl; benzylsulfonyl; phenylsulfonyl; cyano; nitro; amino which is unsubstituted or substituted by one or two identical or different radicals selected from (C1 -C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(C1-C6)alkyl, benzyl and phenyl groups; carboxyl; alkoxycarbonyl in which the alkoxy is (C1-C6); (C2-C6)alkenyloxycarbonyl; (C2-C6)alkynyloxycarbonyl; (C3-C8)cycloalkoxycarbonyl; (C3-C8)cycloalkyl(C1-C6)alkoxycarbonyl; benzyloxycarbonyl; phenoxycarbonyl; and carbamoyl which is unsubstituted or substituted on the amino group by one or two identical or different radicals selected from (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(C1-C6)alkyl, benzyl and phenyl groups;
a group R′″ selected from the following groups: (C1-C6)alkyl substituted by a functional group; (C2-C6)alkenyl substituted by a functional group; (C2-C6)alkynyl substituted by a functional group; phenyl(C1-C6)alkyl substituted on the phenyl by a (C1-C6)alkyl or by a functional group; phenyl(C2-C6)alkenyl substituted on the phenyl by a (C1-C6)alkyl or by a functional group; phenyl(C2-C6)alkennyl substituted on the phenyl by a (C1-C6)alkyl or by a functional group; benzyl substituted on the phenyl by a (C1-C6)alkyl or by a functional group; and phenyl which is unsubstituted or substituted by a (C1-C6)alkyl or by a functional group, the functional group being as defined above;
a group O—R′″, S—R′″, SO—R′″ or SO2—R′″, in which R′″is as defined above;
a group NR′″R0, in which R′″ is as defined above and R0 is hydrogen or is as defined above for R′″, or R′″ and R0, together with the nitrogen to which they are bonded, form a group selected from pyrrolidino, piperidino and morpholino groups;
a group COOR′″ or a group CO—SR′″, in which R′″ is as defined above;
a group CONR′″R0, in which R′″ is as defined above and R0 is hydrogen or is as defined above for R′″, or R′″ and R0, together with the nitrogen to which they are bonded, form a group selected from pyrrolidino, piperidino and morpholino groups;
a group SO2NR′″R0, in which R′″ is as defined above and R0 is hydrogen or is as defined above for R′″, or R′″ and R0, together with the nitrogen to which they are bonded, form a group selected from pyrrolidino, piperidino and morpholino groups;
R″ is hydrogen; a halogen; a (C1-C6)alkyl; a functional group as defined above; a group OR′″, R′″ being as defined above; a group COOR′″, R′″ being as defined above; or a group CONR′″R0, in which R′″ is as defined above and R0 is hydrogen or is as defined above for R′″, or R′″ and R0, together with the nitrogen to which they are bonded, form a group selected from pyrrolidino, piperidino and morpholino groups;
W is a direct bond or an oxygen atom;
X′ is hydrogen, a (C1-C6)alkyl or a (C1-C6)alkylcarbonyl;
Y is hydrogen or a group A′—CH(OH)—CH2—, A′ being identical to A but other than benzofuran-2-yl; or
X′ and Y, taken together, form a methylene group optionally substituted by an alkoxycarbonyl in which the alkoxy is (C1-C6); an ethylene group optionally substituted by an oxo group; or a 1,3-propylene group;
Z is hydrogen or a (C1-C6)alkyl, or one of its pharmaceutically acceptable salts.
25. A pharmaceutical composition according to any one of claims 20 to 22 wherein the β3-agonist is a compound of the formula
in which:
E is hydrogen, a (C1-C4)alkyl, a (C1-C4)alkoxy, a phenyl, a nitro, a halogen atom or a trifluoromethyl;
L is hydrogen, a (C1-C4)alkyl, a (C1-C4)alkoxy, a phenyl, a nitro or a halogen atom; or E and L together are a group —CH═CH—CH═CH— or —CH2—CH2—CH2—CH2—; and
G is hydrogen, a chlorine atom, a hydroxyl or a group OG′, in which G′ is a (C1-C4)alkyl which is unsubstituted or substituted by a hydroxyl, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, carboxyl or (C3-C7)cycloalkyl; a (C3-C7)cycloalkyl; or a (C2-C4)alkanoyl, or one of its pharmaceutically acceptable salts.
26. A pharmaceutical composition according to claim 23 , characterized in that the β3 agonist is N-[(2S)-7-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphth-2-yl]-(2R)-2-(3-chlorophenyl)-2-hydroxyethanamine or one of its pharmaceutically acceptable salts.
27. A pharmaceutical composition according to any one of claims 20 to 26 containing from 0.5 to 600 mg of CB1 receptor antagonist and from 0.5 to 600 mg of β3-agonist.
28. A pharmaceutical composition according to claim 27 containing from 1 to 400 mg of CB1 receptor antagonist and from 2 to 400 mg of β3-agonist.
29. A pharmaceutical composition according to claim 28 containing from 2 to 200 mg of CB1 receptor antagonist and from 10 to 250 mg of β3-agonist.
30. A kit for the treatment of appetency disorders, which contains:
a CB1 receptor antagonist, and
a regulator of metabolic disorders, said active principles being in separate compartments and being intended to be administered simultaneously, sequentially or over a period of time.
31. A kit according to claim 30 in which said regulator of metabolic disorders is a β3-agonist.
32. A kit according to claim 30 or 31 in which said CB1 receptor antagonist is N-piperidino-5-(4-chlorophenyl)- 1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide, one of its pharmaceutically acceptable salts or one of their solvates and said β3-agonist is N-[(2S)-7-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphth-2-yl]-(2R)-2-(3-chlorophenyl)-2-hydroxyethanamine or one of its pharmaceutically acceptable salts.
33. A kit according to any one of claims 30 to 32 in which said active principles are in different packagings.
34. Use according to claim 1 for the preparation of a drug useful for regulating the desire to consume non-essential food items.
35. Use according to claim 34 in which the non-essential food items are excess sugars, excess carbohydrates, alcohol and drugs.
36. Use of a CB1 receptor antagonist for the preparation of a drug useful to suppress spontaneous appetency for a food item which usually brings pleasure.
37. Use according to claim 36 in which the food item found pleasurable is alcohol or sugar.
38. Use according to any one of claims 34 to 37 in which the CB1 receptor antagonist is N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide, one of its pharmaceutically acceptable salts or one of their solvates.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/044,531 US20020128302A1 (en) | 1997-01-28 | 2002-01-11 | Use of central cannabinoid receptor antagonists for the preparation of drugs |
US10/935,250 US20050026986A1 (en) | 1997-01-28 | 2004-09-07 | Use of central cannabinoid receptor antagonists for the preparation of drugs |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9700870A FR2758723B1 (en) | 1997-01-28 | 1997-01-28 | USE OF CENTRAL CANNABINOID RECEPTOR ANTAGONISTS FOR THE PREPARATION OF DRUGS |
FR97/00870 | 1997-01-28 | ||
US09/341,764 US6344474B1 (en) | 1997-01-28 | 1998-01-28 | Use of central cannabinoid receptor antagonists for regulating appetence |
US10/044,531 US20020128302A1 (en) | 1997-01-28 | 2002-01-11 | Use of central cannabinoid receptor antagonists for the preparation of drugs |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1998/000154 Division WO1998032441A1 (en) | 1997-01-28 | 1998-01-28 | Use of central cannabinoid receptor antagonists for regulating appetence |
US09/341,764 Division US6344474B1 (en) | 1997-01-28 | 1998-01-28 | Use of central cannabinoid receptor antagonists for regulating appetence |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/935,250 Continuation US20050026986A1 (en) | 1997-01-28 | 2004-09-07 | Use of central cannabinoid receptor antagonists for the preparation of drugs |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020128302A1 true US20020128302A1 (en) | 2002-09-12 |
Family
ID=9503028
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/341,764 Expired - Fee Related US6344474B1 (en) | 1997-01-28 | 1998-01-28 | Use of central cannabinoid receptor antagonists for regulating appetence |
US10/044,531 Abandoned US20020128302A1 (en) | 1997-01-28 | 2002-01-11 | Use of central cannabinoid receptor antagonists for the preparation of drugs |
US10/935,250 Abandoned US20050026986A1 (en) | 1997-01-28 | 2004-09-07 | Use of central cannabinoid receptor antagonists for the preparation of drugs |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/341,764 Expired - Fee Related US6344474B1 (en) | 1997-01-28 | 1998-01-28 | Use of central cannabinoid receptor antagonists for regulating appetence |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/935,250 Abandoned US20050026986A1 (en) | 1997-01-28 | 2004-09-07 | Use of central cannabinoid receptor antagonists for the preparation of drugs |
Country Status (32)
Country | Link |
---|---|
US (3) | US6344474B1 (en) |
EP (2) | EP0969835B1 (en) |
JP (1) | JP3676383B2 (en) |
AR (1) | AR011776A1 (en) |
AT (1) | ATE358480T1 (en) |
AU (1) | AU6219398A (en) |
BR (1) | BR9806801A (en) |
CA (1) | CA2278661A1 (en) |
DE (1) | DE69837473T2 (en) |
DK (1) | DK0969835T3 (en) |
DZ (1) | DZ2405A1 (en) |
EE (1) | EE04630B1 (en) |
ES (1) | ES2285760T3 (en) |
FR (1) | FR2758723B1 (en) |
GT (1) | GT199800021A (en) |
HK (1) | HK1022829A1 (en) |
HR (1) | HRP980042A2 (en) |
ID (1) | ID22216A (en) |
IS (1) | IS5113A (en) |
LV (1) | LV12354B (en) |
ME (1) | MEP26508A (en) |
MY (1) | MY117251A (en) |
NO (1) | NO323696B1 (en) |
PT (1) | PT969835E (en) |
RS (1) | RS49830B (en) |
SA (1) | SA98181113B1 (en) |
SK (1) | SK99799A3 (en) |
TR (1) | TR199901721T2 (en) |
TW (1) | TW450808B (en) |
UY (1) | UY24847A1 (en) |
WO (1) | WO1998032441A1 (en) |
ZA (1) | ZA98691B (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040077650A1 (en) * | 2002-10-18 | 2004-04-22 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US20040092520A1 (en) * | 2002-10-28 | 2004-05-13 | Pfizer Inc. | Purine compounds and uses thereof |
US20040122074A1 (en) * | 2002-12-12 | 2004-06-24 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US20040157839A1 (en) * | 2003-02-06 | 2004-08-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US20040157838A1 (en) * | 2003-02-10 | 2004-08-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US20040214856A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US20040214838A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US20040214837A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US20040235926A1 (en) * | 2003-05-07 | 2004-11-25 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US20040259887A1 (en) * | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US6930122B2 (en) * | 2000-02-09 | 2005-08-16 | Sanofi-Aventis | Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US20070088058A1 (en) * | 2003-10-30 | 2007-04-19 | Shah Shrenik K | Aralkyl amines as cannabinoid receptor modulators |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
EP1886684A1 (en) * | 2006-08-07 | 2008-02-13 | Ratiopharm GmbH | Pharmaceutical composition comprising rimonabant |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7393842B2 (en) * | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
EP1258253A1 (en) * | 2000-01-28 | 2002-11-20 | Asahi Kasei Kabushiki Kaisha | Novel remedies with the use of beta3 agonist |
GB0010960D0 (en) * | 2000-05-05 | 2000-06-28 | Glaxo Group Ltd | Assay |
FR2809725B1 (en) * | 2000-06-06 | 2004-05-07 | Sanofi Synthelabo | PROPANOLAMINOTETRALINS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
US20020091114A1 (en) | 2000-10-04 | 2002-07-11 | Odile Piot-Grosjean | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
FR2814678B1 (en) † | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | COMBINATION OF AN ANTAGONIST OF THE CB1 RECEPTOR AND SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE FOR THE TREATMENT OF OBESITY |
US8449908B2 (en) | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
US20050154064A1 (en) * | 2001-03-27 | 2005-07-14 | The Regents Of The University Of California | Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism |
US20050054730A1 (en) * | 2001-03-27 | 2005-03-10 | The Regents Of The University Of California | Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha |
KR20030087657A (en) | 2001-03-27 | 2003-11-14 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism |
AU2002319627A1 (en) * | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
US6509367B1 (en) * | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
EP1487436A4 (en) | 2002-03-08 | 2009-06-03 | Signal Pharm Inc | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
EP1496838B1 (en) | 2002-03-12 | 2010-11-03 | Merck Sharp & Dohme Corp. | Substituted amides |
CA2479618A1 (en) * | 2002-03-26 | 2003-10-09 | William K. Hagmann | Spirocyclic amides as cannabinoid receptor modulators |
CA2479744A1 (en) * | 2002-03-28 | 2003-10-09 | Paul E. Finke | Substituted 2,3-diphenyl pyridines |
JP2005527586A (en) * | 2002-04-05 | 2005-09-15 | メルク エンド カムパニー インコーポレーテッド | Substituted arylamides |
AU2003223510B2 (en) * | 2002-04-12 | 2008-05-08 | Merck Sharp & Dohme Corp. | Bicyclic amides |
US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
JP4545584B2 (en) * | 2002-05-17 | 2010-09-15 | デューク ユニバーシティ | Methods for treating obesity |
EP1509250B1 (en) | 2002-06-06 | 2008-05-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods compositions and articles of manufacture for modulating bone growth |
US6972291B2 (en) * | 2002-07-02 | 2005-12-06 | Bernstein Richard K | Method for reducing food intake |
JP4667867B2 (en) | 2002-08-02 | 2011-04-13 | メルク・シャープ・エンド・ドーム・コーポレイション | Substituted furo [2,3-b] pyridine derivatives |
WO2004034968A2 (en) * | 2002-08-20 | 2004-04-29 | The Regents Of The University Of California | Combination therapy for controlling appetites |
AU2003275242B2 (en) | 2002-09-27 | 2010-03-04 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
US7765162B2 (en) * | 2002-10-07 | 2010-07-27 | Mastercard International Incorporated | Method and system for conducting off-line and on-line pre-authorized payment transactions |
US20040122033A1 (en) * | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
EP1575901B1 (en) * | 2002-12-19 | 2012-10-10 | Merck Sharp & Dohme Corp. | Substituted amides |
GB0230088D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
PT2316456T (en) * | 2003-04-29 | 2017-09-05 | Orexigen Therapeutics Inc | Compositions for affecting weight loss comprising an opioid antagonist and bupropion |
US20040224962A1 (en) * | 2003-05-09 | 2004-11-11 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
US20040224963A1 (en) * | 2003-05-09 | 2004-11-11 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
CN1809552A (en) * | 2003-05-20 | 2006-07-26 | 田纳西大学研究基金会 | Cannabinoid derivatives, methods of making, and use thereof |
FR2856683A1 (en) * | 2003-06-25 | 2004-12-31 | Sanofi Synthelabo | 4-CYANOPYRAZOLE-3-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
WO2005020992A1 (en) * | 2003-09-02 | 2005-03-10 | Solvay Pharmaceuticals Gmbh | Novel medical use of selective cb1-receptor antagonists |
US20050239859A2 (en) * | 2003-09-03 | 2005-10-27 | Solvay Pharmaceuticals Gmbh | Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity |
FR2861302A1 (en) * | 2003-10-24 | 2005-04-29 | Sanofi Synthelabo | Use of pyrazole derivative as cannabinoid CB1 receptor antagonist, for treatment and prevention of metabolic syndrome, particularly cardiovascular risks and dyslipidemia associated with obesity |
FR2861300B1 (en) * | 2003-10-24 | 2008-07-11 | Sanofi Synthelabo | USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF METABOLIC SYNDROME |
FR2861301B1 (en) * | 2003-10-24 | 2008-07-11 | Sanofi Synthelabo | USE OF THE PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF METABOLIC SYNDROME. |
RU2006117637A (en) * | 2003-10-24 | 2007-12-10 | Зольвай Фармасьютиклз Гмбх (De) | COMBINED TREATMENT OF OBESITY WITH THE APPLICATION OF SELECTIVE CB1-RECEPTOR ANTAGONISTS AND LIPASE INHIBITORS |
FR2861303A1 (en) * | 2003-10-24 | 2005-04-29 | Sanofi Synthelabo | Use of pyrazole derivative as cannabinoid CB1 receptor antagonist, for treatment and prevention of metabolic syndrome, particularly cardiovascular risks, dyslipidemia and liver disease associated with obesity |
US20050143441A1 (en) * | 2003-10-27 | 2005-06-30 | Jochen Antel | Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity |
US20050124660A1 (en) * | 2003-10-27 | 2005-06-09 | Jochen Antel | Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds |
CA2544191A1 (en) * | 2003-11-04 | 2005-05-26 | Merck & Co., Inc. | Substituted naphthyridinone derivatives |
US20060160750A1 (en) * | 2004-01-13 | 2006-07-20 | Krishnan K R R | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
BRPI0506829A (en) | 2004-01-13 | 2007-05-29 | Univ Duke | Anticonvulsant and antipsychotic drug compositions and methods for their use to affect weight loss |
US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
EP1729762A4 (en) * | 2004-03-31 | 2007-12-19 | Neurogen Corp | Combination therapy for weight management |
US20060100205A1 (en) * | 2004-04-21 | 2006-05-11 | Eckard Weber | Compositions for affecting weight loss |
ES2543836T3 (en) * | 2004-04-23 | 2015-08-24 | Northern Sydney Local Health District | Procedures and compositions for the treatment of myocardial conditions |
CA2565154A1 (en) * | 2004-05-03 | 2005-11-24 | Duke University | Compositions for affecting weight loss |
ITMI20041032A1 (en) * | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | PHARMACEUTICAL COMPOSITES |
BRPI0513104A (en) | 2004-07-12 | 2008-04-29 | Cadila Healthcare Ltd | compound, pharmaceutical composition, method for treating cannabinoid receptor-associated diseases, medicament for treating / reducing cannabinoid receptor-associated diseases, use of compound, process for preparing compound and intermediate |
US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
JP2008509142A (en) * | 2004-08-03 | 2008-03-27 | オレキシジェン・セラピューティクス・インコーポレーテッド | Combination of bupropion and a second compound to affect weight loss |
JP2008514718A (en) * | 2004-09-29 | 2008-05-08 | シェーリング コーポレイション | Combinations of substituted azetidonones and CB1 antagonists |
AU2005298692A1 (en) * | 2004-10-25 | 2006-05-04 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type I, obesity and related conditions |
ES2325773T5 (en) | 2004-11-01 | 2014-02-24 | Amylin Pharmaceuticals, Llc. | Treatment of obesity and related disorders |
US8394765B2 (en) * | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
AU2005305675B2 (en) * | 2004-11-16 | 2012-12-13 | Gw Pharma Limited | New use for cannabinoid |
GB0425248D0 (en) * | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
WO2006060192A2 (en) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Pyrazole derivatives |
US8853205B2 (en) | 2005-01-10 | 2014-10-07 | University Of Connecticut | Heteropyrrole analogs acting on cannabinoid receptors |
US8084451B2 (en) * | 2005-01-10 | 2011-12-27 | University Of Connecticut | Heteropyrrole analogs acting on cannabinoid receptors |
FR2882365B1 (en) * | 2005-02-21 | 2007-09-07 | Sanofi Aventis Sa | 2- (1,5-DIPHENYL-1H-PYRAZOL-3-YL) -1,3,4-OXADIAZOLE DERIVATIVES AND THEIR PREPARATION AND THERAPEUTIC USE |
EP1853264A1 (en) * | 2005-02-21 | 2007-11-14 | Sanofi-Aventis | Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes |
GB0514739D0 (en) * | 2005-07-19 | 2005-08-24 | Astrazeneca Ab | Therapeutic agents |
CA2518579A1 (en) * | 2005-08-05 | 2007-02-05 | University Technologies International Inc. | Method for appetite suppression |
EP2330125A3 (en) | 2005-08-11 | 2012-12-12 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
AU2006279680B2 (en) | 2005-08-11 | 2012-12-06 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
AR056560A1 (en) * | 2005-10-06 | 2007-10-10 | Astrazeneca Ab | PIRROLOPIRIDINONES AS MODULATORS CB1 |
DK2135603T3 (en) | 2005-11-22 | 2013-03-25 | Orexigen Therapeutics Inc | Compositions and Methods for Increasing Insulin Sensitivity |
WO2007139062A1 (en) * | 2006-05-30 | 2007-12-06 | Kyorin Pharmaceutical Co., Ltd. | Therapeutic agent for obesity, and method for treatment and prevention of obesity |
GB2438682A (en) * | 2006-06-01 | 2007-12-05 | Gw Pharma Ltd | New use for cannabinoids |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
JO3598B1 (en) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | Boronic acids and esters as inhibitors of fatty acid amide hydrolase |
AU2007319472B2 (en) | 2006-11-09 | 2013-01-17 | Nalpropion Pharmaceuticals Llc | Methods Of Administering Weight Loss Medications |
CN101588795A (en) | 2006-11-09 | 2009-11-25 | 奥雷西根治疗公司 | Wo2008055686 |
FR2914554B1 (en) * | 2007-04-05 | 2009-07-17 | Germitec Soc Par Actions Simpl | METHOD OF MONITORING THE USE OF A MEDICAL DEVICE. |
PE20090142A1 (en) * | 2007-04-11 | 2009-02-19 | Merck & Co Inc | DERIVATIVES OF FURO [2,3-B] PYRIDINE SUBSTITUTED AS MODULATORS OF THE CANABINOID-1 RECEPTOR |
GB2450753B (en) * | 2007-07-06 | 2012-07-18 | Gw Pharma Ltd | New Pharmaceutical formulation |
DK2176208T3 (en) * | 2007-07-30 | 2015-04-27 | Zynerba Pharmaceuticals Inc | Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof |
WO2009064298A1 (en) * | 2007-11-14 | 2009-05-22 | Amylin Pharmaceuticals, Inc. | Methods for treating obesity and obesity related diseases and disorders |
US20090247619A1 (en) * | 2008-03-06 | 2009-10-01 | University Of Kentucky | Cannabinoid-Containing Compositions and Methods for Their Use |
WO2009126691A1 (en) * | 2008-04-09 | 2009-10-15 | Infinity Pharmaceuticals, Inc | Inhibitors of fatty acid amide hydrolase |
US20110144145A1 (en) * | 2008-05-30 | 2011-06-16 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
WO2010079241A1 (en) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Use of antagonists and/or inverse agonists of cb1 receptors for the preparation of drugs that increase motor neuron excitability |
US10053444B2 (en) | 2009-02-19 | 2018-08-21 | University Of Connecticut | Cannabinergic nitrate esters and related analogs |
AU2010234449A1 (en) | 2009-04-07 | 2011-11-03 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
AU2010234445A1 (en) | 2009-04-07 | 2011-11-03 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
US8765735B2 (en) * | 2009-05-18 | 2014-07-01 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
US9149465B2 (en) * | 2009-05-18 | 2015-10-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
US8927551B2 (en) * | 2009-05-18 | 2015-01-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
WO2011067225A1 (en) | 2009-12-01 | 2011-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions targeting cb1 receptor for controlling food intake |
AU2011203867B2 (en) | 2010-01-11 | 2015-12-03 | Nalpropion Pharmaceuticals Llc | Methods of providing weight loss therapy in patients with major depression |
JP2013518886A (en) | 2010-02-03 | 2013-05-23 | インフイニトイ プハルマセウトイカルス インコーポレイテッド | Fatty acid amide hydrolase inhibitor |
BR112014003886B1 (en) | 2011-08-19 | 2022-04-19 | Universita Degli Studi Di Urbino ''carlo Bo'' | Compound, pharmaceutical composition, and use of a compound |
US9630979B2 (en) | 2011-09-29 | 2017-04-25 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
EP2858640B1 (en) | 2012-06-06 | 2020-03-25 | Nalpropion Pharmaceuticals LLC | Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk |
ES2908240T3 (en) | 2014-04-07 | 2022-04-28 | Univ California | Fatty acid amide hydrolase (FAAH) enzyme inhibitors with improved oral bioavailability and their use as medicaments |
CA3125847A1 (en) | 2020-07-27 | 2022-01-27 | Makscientific, Llc | Process for making biologically active compounds and intermediates thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4707497A (en) * | 1985-07-10 | 1987-11-17 | Sanofi | Phenylethanolaminotetralines, a process for their preparation and pharmaceutical compositions containing them |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE65511B1 (en) * | 1989-12-29 | 1995-11-01 | Sanofi Sa | New phenylethanolaminomethyltetralins |
FR2713225B1 (en) * | 1993-12-02 | 1996-03-01 | Sanofi Sa | Substituted N-piperidino-3-pyrazolecarboxamide. |
FR2692575B1 (en) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | NOVEL PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
EP0627407A1 (en) * | 1993-05-28 | 1994-12-07 | MIDY S.p.A. | (7S)-7-(2(3-chlorophenyl)-2-hydroethylamino-5,6,7,8-tetrahydro-naphthalen-2-yloxy acetic acid, their pharmaceutically acceptable salts with a beta-3-adrenergic agonist activity and pharmaceutical compositions containing them |
US5578638A (en) * | 1993-11-05 | 1996-11-26 | American Cyanamid Company | Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists |
EP0795327A1 (en) * | 1996-03-13 | 1997-09-17 | Pfizer Inc. | Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin |
-
1997
- 1997-01-28 FR FR9700870A patent/FR2758723B1/en not_active Expired - Fee Related
-
1998
- 1998-01-20 UY UY24847A patent/UY24847A1/en not_active Application Discontinuation
- 1998-01-26 MY MYPI98000368A patent/MY117251A/en unknown
- 1998-01-27 DZ DZ980015A patent/DZ2405A1/en active
- 1998-01-27 HR HR9700870A patent/HRP980042A2/en not_active Application Discontinuation
- 1998-01-27 AR ARP980100350A patent/AR011776A1/en unknown
- 1998-01-28 ZA ZA98691A patent/ZA98691B/en unknown
- 1998-01-28 BR BR9806801-6A patent/BR9806801A/en not_active Application Discontinuation
- 1998-01-28 ID IDW990761A patent/ID22216A/en unknown
- 1998-01-28 US US09/341,764 patent/US6344474B1/en not_active Expired - Fee Related
- 1998-01-28 CA CA002278661A patent/CA2278661A1/en not_active Abandoned
- 1998-01-28 DK DK98904238T patent/DK0969835T3/en active
- 1998-01-28 ME MEP-265/08A patent/MEP26508A/en unknown
- 1998-01-28 EP EP98904238A patent/EP0969835B1/en not_active Expired - Lifetime
- 1998-01-28 SK SK997-99A patent/SK99799A3/en unknown
- 1998-01-28 ES ES98904238T patent/ES2285760T3/en not_active Expired - Lifetime
- 1998-01-28 DE DE69837473T patent/DE69837473T2/en not_active Expired - Fee Related
- 1998-01-28 EE EEP199900304A patent/EE04630B1/en not_active IP Right Cessation
- 1998-01-28 JP JP53169398A patent/JP3676383B2/en not_active Expired - Fee Related
- 1998-01-28 WO PCT/FR1998/000154 patent/WO1998032441A1/en active Application Filing
- 1998-01-28 RS YUP-350/99A patent/RS49830B/en unknown
- 1998-01-28 TR TR1999/01721T patent/TR199901721T2/en unknown
- 1998-01-28 AT AT98904238T patent/ATE358480T1/en not_active IP Right Cessation
- 1998-01-28 EP EP07105573A patent/EP1795194A3/en not_active Withdrawn
- 1998-01-28 PT PT98904238T patent/PT969835E/en unknown
- 1998-01-28 AU AU62193/98A patent/AU6219398A/en not_active Abandoned
- 1998-01-28 GT GT199800021A patent/GT199800021A/en unknown
- 1998-02-17 TW TW087101128A patent/TW450808B/en not_active IP Right Cessation
- 1998-04-21 SA SA98181113A patent/SA98181113B1/en unknown
-
1999
- 1999-07-12 IS IS5113A patent/IS5113A/en unknown
- 1999-07-27 LV LVP-99-114A patent/LV12354B/en unknown
- 1999-07-27 NO NO19993634A patent/NO323696B1/en not_active IP Right Cessation
-
2000
- 2000-03-22 HK HK00101771A patent/HK1022829A1/en not_active IP Right Cessation
-
2002
- 2002-01-11 US US10/044,531 patent/US20020128302A1/en not_active Abandoned
-
2004
- 2004-09-07 US US10/935,250 patent/US20050026986A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4707497A (en) * | 1985-07-10 | 1987-11-17 | Sanofi | Phenylethanolaminotetralines, a process for their preparation and pharmaceutical compositions containing them |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050187253A1 (en) * | 2000-02-09 | 2005-08-25 | Sanofi-Aventis | Medicinal kit to quit tobacco consumption comprising central cannabinoid receptor antagonist |
US6930122B2 (en) * | 2000-02-09 | 2005-08-16 | Sanofi-Aventis | Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation |
US20040077650A1 (en) * | 2002-10-18 | 2004-04-22 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US20040092520A1 (en) * | 2002-10-28 | 2004-05-13 | Pfizer Inc. | Purine compounds and uses thereof |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US20040122074A1 (en) * | 2002-12-12 | 2004-06-24 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US20040157839A1 (en) * | 2003-02-06 | 2004-08-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US20040157838A1 (en) * | 2003-02-10 | 2004-08-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US20040214838A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US20040214837A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7354929B2 (en) | 2003-04-23 | 2008-04-08 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US20040214856A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US20070105856A1 (en) * | 2003-04-23 | 2007-05-10 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US20040235926A1 (en) * | 2003-05-07 | 2004-11-25 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US20040259887A1 (en) * | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US20070088058A1 (en) * | 2003-10-30 | 2007-04-19 | Shah Shrenik K | Aralkyl amines as cannabinoid receptor modulators |
US7390835B2 (en) | 2003-10-30 | 2008-06-24 | Merck & Co., Inc. | Aralkyl amines as cannabinoid receptor modulators |
EP1886684A1 (en) * | 2006-08-07 | 2008-02-13 | Ratiopharm GmbH | Pharmaceutical composition comprising rimonabant |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6344474B1 (en) | Use of central cannabinoid receptor antagonists for regulating appetence | |
EP1257275B1 (en) | Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation | |
EP3132792B1 (en) | Composition and methods for increasing insulin sensitivity | |
US20060058293A1 (en) | Combination of bupropion and a second compound for affecting weight loss | |
US20070129283A1 (en) | Compositions and methods for reducing food cravings | |
AU2006275914A1 (en) | Compositions for affecting weight loss | |
US20090281143A1 (en) | Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity | |
BG63803B1 (en) | Farmaceutical composition for the prevention and treatment of diabetic complications | |
US6235793B1 (en) | Use of agonists of adrenergic β-3 receptors for preparing wound-healing medicines | |
MXPA99006785A (en) | Use of central cannabinoid receptor antagonists for regulating appetence |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |